As of 2025-07-21, the Intrinsic Value of Jenburkt Pharmaceuticals Ltd (524731.BO) is 927.43 INR. This 524731.BO valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 1,306.00 INR, the upside of Jenburkt Pharmaceuticals Ltd is -29.00%.
The range of the Intrinsic Value is 782.08 - 1,164.29 INR
Based on its market price of 1,306.00 INR and our intrinsic valuation, Jenburkt Pharmaceuticals Ltd (524731.BO) is overvalued by 29.00%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 782.08 - 1,164.29 | 927.43 | -29.0% |
| DCF (Growth 10y) | 854.00 - 1,215.45 | 993.43 | -23.9% |
| DCF (EBITDA 5y) | 1,058.98 - 1,444.54 | 1,300.41 | -0.4% |
| DCF (EBITDA 10y) | 1,026.07 - 1,404.98 | 1,239.14 | -5.1% |
| Fair Value | 1,242.31 - 1,242.31 | 1,242.31 | -4.88% |
| P/E | 1,290.84 - 2,217.34 | 1,617.15 | 23.8% |
| EV/EBITDA | 821.03 - 1,363.24 | 1,127.65 | -13.7% |
| EPV | 539.89 - 650.35 | 595.12 | -54.4% |
| DDM - Stable | 246.02 - 487.23 | 366.62 | -71.9% |
| DDM - Multi | 270.17 - 422.01 | 329.84 | -74.7% |
| Market Cap (mil) | 5,759.46 |
| Beta | 1.01 |
| Outstanding shares (mil) | 4.41 |
| Enterprise Value (mil) | 5,551.94 |
| Market risk premium | 8.31% |
| Cost of Equity | 20.56% |
| Cost of Debt | 7.48% |
| WACC | 13.07% |